DRKS00026119已完成4 期
Prospective study on the long-term clinical performance of monolithic three-unit bridges made of IPS e.max ZirCAD Prime
Firma Ivoclar Vivadent0 个研究点目标入组 22 人开始时间: 2021年8月17日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •older than 18 years
- •- no change of residence planned
- •- appealing oral hygiene
- •- Indication for an all-ceramic bridge in the posterior region;
- •- no parafunctions (bruxism);
- •- periodontally healthy/restored (max. degree of looseness 1) and
- •- Patients who are not pregnant or breastfeeding at the time of admission
排除标准
- •- younger than 18 years
- •- change of residence planned
- •- non-responsive oral hygiene
- •- no indication for an all-ceramic bridge in the posterior region;
- •- Parafunctions (bruxism);
- •- periodontally not healthy/restored (at least degree of looseness 1) and
- •- Patients who are pregnant at the time of admission
研究者
相似试验
招募中
不适用
A prospective study to evaluate long-term clinical outcomes of the GTS cementless femoral stemJoint wear10023213OsteoarthritisNL-OMON55672Zimmer Biomet23
尚未招募
不适用
A study of outcome and Quality of Life assessment in patients with chronic allergy after nasal irrigation using normal saline with budesonide after endoscopic nose surgeryCTRI/2019/02/017402JLN MEDICAL COLLEGE
招募中
不适用
Role of steroids in IgA nephropathy and correlation with Oxford MEST ClassificatioCTRI/2017/02/007768Department of NephrologyIPGMER Kolkata30
尚未招募
Unknown
Clinical study on long-term follow-up of patients treated with PDTJPRN-UMIN000048941agasaki-university hospital40
进行中（未招募）
不适用
Clinical Study to Investigate the Long-Term Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients with Severe Haemophilia A – Extension Study to GENA-01Severe haemophilia A (FVIII:C <1%)MedDRA version: 12.1Level: LLTClassification code 10018937Term: Haemophilia AEUCTR2010-023242-69-DEOctapharma AG25